Navigation Links
Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
Date:12/5/2012

LAUSANNE, Switzerland, December 5, 2012 /PRNewswire/ --

Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"):

  • New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats.
  • Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial business. 

Accurate and fast validation of biomarkers; increasing efficiency in Research and Drug Development

DMAT is an innovative and integrated detection platform for high-quality biomarker analysis. It enables accelerated development of multiplex assays where several biomarkers can be analyzed at the same time. DMAT dramatically reduces hands-on time and allows users to perform bioassays far more quickly and cost-effectively than with other systems, while ensuring optimal accuracy.

"This revolutionary technology will accelerate the conversion of biomarker discoveries into clinical practice and will help scientists deliver more quickly the promise of personalized medicine," said Biocartis CEO Dr. Greg Parekh. "DMAT is complementary with protein biomarker discovery and next generation sequencing, because the ease of use, sensitivity and accuracy enables rapid validation of new biomarkers initially identified on these other platforms."

Innovative detection technology combining reproducibility, speed and multiplexing

Conceived in 2007 and developed under design control, DMAT leverages advanced semi-conductor technologies and micro-fluidics to provide fast, flexible and multiplexed detection and quantification of nucleic acid and protein based biomarkers. The platform accelerates biomarker research and yields robust and highly reproducible data over a wide range of analyte concentrations. Demonstrating concordance between single-plex and multiplex assays, the DMAT platform can measure over 2000 analytes simultaneously without deterioration in performance.

For Research Use Only ("RUO")

The DMAT platform is initially targeting the research market. As such, Biocartis is offering customizable generic test consumables to maximize application flexibility. Biocartis is additionally developing a menu of important RUO assays including a cytokine panel, an oncogene panel and a cell signaling panel.

With the commercialization of DMAT, Biocartis is scaling up its sales force to initially target the Preclinical, Clinical Development and Clinical Research markets. 

http://www.biocartis.com


'/>"/>
SOURCE Biocartis
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
2. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
3. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
4. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
5. The Scientist Proudly Announces the Top 10 Innovations of 2012
6. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
9. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
10. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):